Welcome to our dedicated page for Caring Brands SEC filings (Ticker: CBRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caring Brands, Inc. (CBRA) uses SEC filings to document its activities as a Nevada-incorporated issuer of common stock. This page brings together the company’s registration statements, current reports, and related exhibits so that investors can review how Caring Brands, Inc. structures its offerings, interacts with underwriters, and manages its stock exchange listings.
The company’s Form S-1/A registration statements outline a public offering of up to 1,000,000 shares of common stock, par value $0.001 per share, through a firm commitment underwriting. These filings also register additional shares for resale by existing stockholders, including shares issuable upon exercise of warrants that originated in earlier private placements conducted by a related Florida corporation. The S-1/A explains the dual prospectus structure, distinguishing between the public offering prospectus and the resale prospectus, and details items such as use of proceeds, underwriting terms, and risk factors.
A Form 8-K filed by Caring Brands, Inc. reports the execution of the underwriting agreement with D. Boral Capital LLC, the closing of the public offering, and the issuance of an underwriter warrant that allows the underwriter to purchase a specified number of common shares at a fixed exercise price for a multi-year term. The same report notes that the company’s common stock was approved for listing on The Nasdaq Stock Market LLC under the symbol CABR and that trading on Nasdaq commenced on a stated date. Press releases announcing the pricing and closing of the offering are attached as exhibits.
On Stock Titan, each new Caring Brands, Inc. filing from the SEC’s EDGAR system is captured and presented with AI-powered summaries that explain the key points in clear language. Whether you are reviewing an S-1/A amendment, a current report on Form 8-K, or exhibits such as the underwriting agreement and underwriter warrant, the platform highlights essential terms, lock-up provisions, registration rights, and listing details. This helps investors understand how CBRA’s and CABR’s regulatory filings relate to the company’s capital structure and trading status without having to parse every page of the original documents.
Caring Brands, Inc. reported an insider ownership update through a Form 3. Director Christopher Galeta is identified as a reporting person in relation to Caring Brands, Inc. as of the event date 10/30/2025. The filing states in the explanation of responses that no securities are beneficially owned, meaning the director reports holding no shares or derivative securities of the company at this time.
Caring Brands, Inc. filed an initial ownership report showing that a reporting person who is both a director and a 10% owner holds a significant stake in the company. As of the event date of 10/30/2025, this individual beneficially owns 2,000,000 shares of common stock, held directly. No derivative securities such as options or warrants are reported in the filing. This Form 3 establishes the insider’s starting ownership position now that they are subject to insider reporting rules.
Caring Brands, Inc. filed its Q3 2025 10‑Q reporting minimal revenue and continued losses. For the three months ended September 30, 2025, net sales were $740 and net loss was $1,018,768. Selling, general and administrative expenses were $999,923, driven by legal, consulting and investor relations costs. For the nine months, revenue totaled $3,795 and net loss was $2,218,121.
Cash was $16,123 as of September 30, 2025, with total current liabilities of $570,210. The company drew $120,000 on a convertible note carrying 10% interest and issued 200,000 warrants at $4.00; related‑party loans totaled $129,405, including $75,000 from executives and $54,405 paid by an affiliate. It recorded $225,000 year‑to‑date amortization on a $3,000,000 NovoDX license (net carrying amount $2,625,000). Management disclosed a going concern uncertainty and a material weakness in internal controls. Shares outstanding were 13,736,925 as of September 30, 2025.
Caring Brands, Inc. filed an amended S-1 registration indicating 13,736,925 shares of common stock issued and outstanding as of October 9, 2025. The filing shows an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, implying a public offering structure that yields $3,680,000 before expenses on the stated tranche. The company reports historical operating losses and working capital movement, with reported changes in cash of $(395,105) and $305,284 for the presented periods.
The company holds an exclusive license and subsequently acquired assets for the product Photocil (license in July 2021; asset acquisition in June 2022), launched commercially in India in September 2022 and initially entered the U.S. via Amazon in Q4 2022 before removal from the U.S. market in 2023 due to insufficient sales. Management plans to apply for a National Drug Code (NDC) number prior to any U.S. relaunch. The filing discloses clinical trial publications and a reported p-value p < 0.03 cited as statistically significant. A new Chief Financial Officer, Tyler Moore, was appointed effective September 4, 2025.
Caring Brands, Inc. (CBRA) filed an amendment to its S-1 registration describing a planned offering and company history. As of September 5, 2025 the company had 13,736,925 shares of common stock issued and outstanding. The prospectus shows a public offering price implied at $4.00 per share with an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, totaling proceeds of $3,680,000 (with related underwriting fees of $320,000). The filing discloses outstanding warrants to purchase up to 2,110,000 shares at $3.00 (expiring May 1, 2027) and 200,000 warrants at $4.00 (expiring August 6, 2030).
The company acquired Photocil assets in June 2022 after obtaining an exclusive license in July 2021, launched the product in India in September 2022 (OTC) and entered the U.S. market in Q4 2022 but removed it from the U.S. market in early/mid 2023 because of insufficient sales. The filing states plans to apply for an NDC for FDA registration prior to a U.S. relaunch. Clinical trial publications and a reported p-value 0.03 are referenced.
Caring Brands, Inc. (CBRA) amended its S-1 registration to detail an offering and provide updated corporate and financial information. The company reports 13,736,925 shares of common stock outstanding as of September 5, 2025, and discloses outstanding warrants to purchase up to 2,110,000 shares at $3.00 (expiring May 1, 2027) and 200,000 warrants at $4.00 (expiring August 6, 2030). The prospectus shows an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, with aggregate proceeds before expenses shown as $3,680,000. Financial excerpts show operating losses, limited revenue and cash activity, including an increase (decrease) in cash of $(395,105) and $305,284 in comparative periods. The filing describes the Photocil asset acquisition and exclusive license history, past U.S. commercialization and removal from the U.S. market due to insufficient sales, and plans to seek an NDC for a U.S. relaunch. Corporate governance, board composition, committees, related party transaction disclosure and disclosure of potential licensing discussions in Europe and South America are included.